131 related articles for article (PubMed ID: 14674041)
1. MRS study on lentiform nucleus in idiopathic Parkinson's disease with unilateral symptoms.
Zheng XN; Zhu XC; Ruan LX; Zhang LJ; Yuan M; Shang DS; Liu Y
J Zhejiang Univ Sci; 2004 Feb; 5(2):246-50. PubMed ID: 14674041
[TBL] [Abstract][Full Text] [Related]
2. Detection and application of neurochemical profile by multiple regional
Guan J; Rong Y; Wen Y; Wu H; Qin H; Zhang Q; Chen W
Brain Behav; 2017 Sep; 7(9):e00792. PubMed ID: 28948086
[TBL] [Abstract][Full Text] [Related]
3. Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy.
Federico F; Simone IL; Lucivero V; De Mari M; Giannini P; Iliceto G; Mezzapesa DM; Lamberti P
J Neurol Neurosurg Psychiatry; 1997 Mar; 62(3):239-42. PubMed ID: 9069478
[TBL] [Abstract][Full Text] [Related]
4. Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study.
Ellis CM; Lemmens G; Williams SC; Simmons A; Dawson J; Leigh PN; Chaudhuri KR
Neurology; 1997 Aug; 49(2):438-44. PubMed ID: 9270574
[TBL] [Abstract][Full Text] [Related]
5. Proton MR spectroscopic imaging of the striatum in Parkinson's disease.
Cruz CJ; Aminoff MJ; Meyerhoff DJ; Graham SH; Weiner MW
Magn Reson Imaging; 1997; 15(6):619-24. PubMed ID: 9285801
[TBL] [Abstract][Full Text] [Related]
6. Neuronal laterality in Parkinson's disease with unilateral symptom by in vivo 1H magnetic resonance spectroscopy.
Choe BY; Park JW; Lee KS; Son BC; Kim MC; Kim BS; Suh TS; Lee HK; Shinn KS
Invest Radiol; 1998 Aug; 33(8):450-5. PubMed ID: 9704284
[TBL] [Abstract][Full Text] [Related]
7. Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy.
Clarke CE; Lowry M; Horsman A
Mov Disord; 1997 May; 12(3):297-301. PubMed ID: 9159722
[TBL] [Abstract][Full Text] [Related]
8. A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease.
Taylor-Robinson SD; Turjanski N; Bhattacharya S; Seery JP; Sargentoni J; Brooks DJ; Bryant DJ; Cox IJ
Metab Brain Dis; 1999 Mar; 14(1):45-55. PubMed ID: 10348313
[TBL] [Abstract][Full Text] [Related]
9. Glutamate measurement in Parkinson's disease using MRS at 3 T field strength.
Kickler N; Krack P; Fraix V; Lebas JF; Lamalle L; Durif F; Krainik A; Rémy C; Segebarth C; Pollak P
NMR Biomed; 2007 Dec; 20(8):757-62. PubMed ID: 17334978
[TBL] [Abstract][Full Text] [Related]
10. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration.
Tedeschi G; Litvan I; Bonavita S; Bertolino A; Lundbom N; Patronas NJ; Hallett M
Brain; 1997 Sep; 120 ( Pt 9)():1541-52. PubMed ID: 9313638
[TBL] [Abstract][Full Text] [Related]
11. Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy.
Clarke CE; Lowry M
Eur J Neurol; 2000 Nov; 7(6):661-5. PubMed ID: 11136352
[TBL] [Abstract][Full Text] [Related]
12. Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders.
Federico F; Simone IL; Lucivero V; Iliceto G; De Mari M; Giannini P; Mezzapesa DM; Tarantino A; Lamberti P
Mov Disord; 1997 Nov; 12(6):903-9. PubMed ID: 9399213
[TBL] [Abstract][Full Text] [Related]
13. [Magnetic resonance spectroscopy in Parkinson's disease and multiple system atrophy].
Aotsuka A; Shinotoh H; Hattori T
Nihon Rinsho; 1997 Jan; 55(1):249-54. PubMed ID: 9014459
[TBL] [Abstract][Full Text] [Related]
14. Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting.
Almuqbel M; Melzer TR; Myall DJ; MacAskill MR; Pitcher TL; Livingston L; Wood KL; Keenan RJ; Dalrymple-Alford JC; Anderson TJ
Parkinsonism Relat Disord; 2016 Jan; 22():54-61. PubMed ID: 26627939
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of proton and phosphorus MR spectroscopic imaging for early diagnosis of Parkinson's disease.
Weiduschat N; Mao X; Beal MF; Nirenberg MJ; Shungu DC; Henchcliffe C
J Neuroimaging; 2015; 25(1):105-10. PubMed ID: 24325203
[TBL] [Abstract][Full Text] [Related]
16. Reduction in temporal N-acetylaspartate and creatine (or choline) ratio in temporal lobe epilepsy: does this 1H-magnetic resonance spectroscopy finding mean poor seizure control?
Mendes-Ribeiro JA; Soares R; Simões-Ribeiro F; Guimarães ML
J Neurol Neurosurg Psychiatry; 1998 Oct; 65(4):518-22. PubMed ID: 9771777
[TBL] [Abstract][Full Text] [Related]
17. Whole-brain proton MR spectroscopic imaging in Parkinson's disease.
Levin BE; Katzen HL; Maudsley A; Post J; Myerson C; Govind V; Nahab F; Scanlon B; Mittel A
J Neuroimaging; 2014; 24(1):39-44. PubMed ID: 23228009
[TBL] [Abstract][Full Text] [Related]
18. Proton MR spectroscopic changes in Parkinson's diseases after thalamotomy.
Baik HM; Choe BY; Son BC; Jeun SS; Kim MC; Lee KS; Kim BS; Lee JM; Lee HK; Suh TS
Eur J Radiol; 2003 Sep; 47(3):179-87. PubMed ID: 12927660
[TBL] [Abstract][Full Text] [Related]
19. Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson's disease patients.
Lucetti C; Del Dotto P; Gambaccini G; Bernardini S; Bianchi MC; Tosetti M; Bonuccelli U
Neurol Sci; 2001 Feb; 22(1):69-70. PubMed ID: 11487206
[TBL] [Abstract][Full Text] [Related]
20. MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury.
Elias AE; Carlos RC; Smith EA; Frechtling D; George B; Maly P; Sundgren PC
Acad Radiol; 2011 Sep; 18(9):1101-8. PubMed ID: 21820634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
